Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maralixibat in Progressive Familial Intrahepatic Cholestasis (PFIC) Extension Study
NCT04185363Phase 3Completed
- Sponsor
- Mirum Pharmaceuticals, Inc.
- Start
- Jan 2020
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 3, open-label, single-arm trial of maralixibat in progressive familial intrahepatic cholestasis (PFIC), sponsored by Mirum Pharmaceuticals, Inc. Primary endpoint: Mean Change From Baseline Over Time in the Average Morning ItchRO(Obs) Severity Score. Started Jan 2020; status: completed.
02
Drugs
maralixibat
03
Conditions
progressive familial intrahepatic cholestasis (PFIC)
Beyond the preview
Go deeper on NCT04185363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04185363.